Japanese drugmaker Eisai has started the rolling submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Leqembi (l 15 May 2024
Accord BioPharma—the US specialty division of Intas Pharmaceuticals— has won US Food and Drug Administration (FDA) approval for Hercessi (trastuzumab-strf), a b 9 May 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.